Login to Your Account

Pharma: Clinic Roundup

Wednesday, October 3, 2012
• Janssen Research & Development LLC, of Raritan, N.J., a unit of Johnson & Johnson, reported that canagliflozin substantially lowered blood glucose levels when used as add-on therapy in patients on insulin therapy for Type II diabetes and who are considered to be at greater risk for cardiovascular disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription